FDA Approves Subcutaneous Formulation of EGFR-targeted Therapy for Non-small Cell Lung Cancer
Patients now have the option of receiving the bispecific antibody amivantamab as an injection. The U.S. Food and Drug...
Progress Against Cancer
Patients now have the option of receiving the bispecific antibody amivantamab as an injection. The U.S. Food and Drug...
The FDA has converted the accelerated approval of rucaparib to full approval for certain patients with metastatic castration-resistant prostate...
Fam-trastuzumab deruxtecan-nxki (T-DXd) with pertuzumab was approved to treat metastatic HER2-positive breast cancer. The U.S. Food and Drug Administration...
The FDA approved a combination of the PARP inhibitor niraparib with a hormone therapy agent plus a corticosteroid for...
Lisocabtagene maraleucel was granted approval for adults with treatment-resistant marginal zone lymphoma. The U.S. Food and Drug Administration (FDA)...
Pirtobrutinib was approved for certain relapsed/refractory chronic lymphocytic leukemias or small lymphocytic lymphomas. The U.S. Food and Drug Administration...
Durvalumab was approved as neoadjuvant and adjuvant treatment with chemotherapy for resectable gastric or gastroesophageal junction cancer. The U.S....
The combination therapy is approved for pre- and post-surgery bladder cancer treatment. The U.S. Food and Drug Administration (FDA)...
The FDA has converted the accelerated approval of tarlatamab-dlle to a full approval for previously treated adults with extensive-stage...
The FDA granted accelerated approval to sevabertinib for previously treated adults with HER2‑mutant non‑squamous non‑small cell lung cancer. The...